In another case-control study, 35 women with breast cancer receiving an aromatase inhibitor and 35 healthy controls underwent detailed neuropsychological testing and FDG PET at baseline prior to commencing aromatase inhibition and 6 months after commencement. The gene discussed is CYP19A1; the disease is breast carcinoma.